UroVysion, urine cytology, and the College of American Pathologists: where should we go from here?
Abstract UroVysion (Abbott Molecular Inc, Des Plaines, Illinois) is a US Food and Drug Administration-approved test for the diagnosis of urothelial carcinoma. Although widely used, there are a variety of different ways to evaluate and interpret the test, and questions remain about the test's cost effectiveness and reproducibility in actual clinical practice. I suggest that the College of American Pathologists has a unique opportunity to create educational programs focusing on borderline or difficult urine cytology and UroVysion samples to provide data upon which to make evidence-based decisions concerning the best use of these tests.
Renshaw
Andrew A
AA
D002295:Carcinoma, Transitional Cell / Q000175:diagnosis* / Q000652:urine; D002986:Clinical Trials as Topic; D003581:Cytodiagnosis / Q000592:standards*; D004502:Education, Medical, Continuing; D006417:Hematuria / Q000175:diagnosis; D006801:Humans; D011237:Predictive Value of Tests; D012955:Societies, Medical; D014481:United States; D014486:United States Food and Drug Administration; D016482:Urinalysis / Q000592:standards*; D001749:Urinary Bladder Neoplasms / Q000175:diagnosis* / Q000652:urine; D014556:Urine / Q000166:cytology*; D019459:Urothelium / Q000473:pathology